A randomized, double blind, placebo-controlled, multicenter, phase III study comparing the activity of paclitaxel plus trastuzumab plus lapatinib to paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis
- 21 Dec 2018 Planned End Date changed from 31 Dec 2017 to 1 Apr 2019.
- 26 Jan 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2017.
- 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History